141 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Article Searches
Core Biotech Buys #16: Taking Advantage Of Weakness To Add To Conviction Ideas https://seekingalpha.com/article/4176184-core-biotech-buys-16-taking-advantage-weakness-add-conviction-ideas?source=feed_all_articles May 22, 2018 - Recent weakness in the biotech sector is an opportunity to add to conviction holdings.My ¨Week in Review¨ blog post appears to have the makings of a permanent feature due to positive feedback received
Lucky Seven: Bio Struggles, Achaogen Breaks Key Support https://seekingalpha.com/article/4176031-lucky-seven-bio-struggles-achaogen-breaks-key-support?source=feed_all_articles May 21, 2018 - Achaogen breaks key support.Aimmune Therapeutics is a buy.Immune Design keeps its head above water.
Lucky Seven: Exelixis Bounces Back, Global Blood Therapeutics Bleeds https://seekingalpha.com/article/4175647-lucky-seven-exelixis-bounces-back-global-blood-therapeutics-bleeds?source=feed_all_articles May 19, 2018 - Immune Design and Viking Therapeutics are added to the win column.Exelixis makes up for its lost ground and is grounded on concrete support.As predicted, shares in Global Blood Therapeutics bled late
Lucky Seven: Immune Design Takes Off, Institutions Place Bets On Viking Therapeutics https://seekingalpha.com/article/4174541-lucky-seven-immune-design-takes-institutions-place-bets-viking-therapeutics?source=feed_all_articles May 16, 2018 - Immune Design is beginning to run.Institutions place their bets on Viking Therapeutics. We will also do so, again.Array BioPharma becomes our second win.ChemoCentryx seems undervalued.
JF's Core Biotech Buys #15: Removal Of A Key Overhang, Buying Weakness In I-O, Updates And Adding To 2 Positions https://seekingalpha.com/article/4173708-jfs-core-biotech-buys-15-removal-key-overhang-buying-weakness-o-updates-adding-2-positions?source=feed_all_articles May 14, 2018 - Although this series is focused on the long term I continue to be pleased with our performance so far.President Trump´s speech on drug prices removed a key overhang for biotech (please see my blog pos
Lucky Seven: Achaogen Likely To Bounce Back https://seekingalpha.com/article/4173647-lucky-seven-achaogen-likely-bounce-back?source=feed_sector_healthcare May 14, 2018 - We have reasons to believe Achaogen will bounce back and resume its upward momentum. In anticipation of this, Achaogen will replace Omeros in the Lucky Seven portfolio. Shares in Global Blood Therapeu
Lucky Seven: Omeros Pops, Exelixis Drops On Phase 3 Flop https://seekingalpha.com/article/4173163-lucky-seven-omeros-pops-exelixis-drops-phase-3-flop?source=feed May 12, 2018 - Viking Therapeutics faces key resistance.Omeros reports Q1 earnings - continues its strong ascent.Array BioPharma springs off support.Exelixis, in collaboration with Roche, failed a phase 3 trial. The
Array BioPharma (ARRY) in Focus: Stock Moves 5.5% Higher http://www.zacks.com/stock/news/303223/array-biopharma-arry-in-focus-stock-moves-55-higher?cid=CS-ZC-FT-303223 May 11, 2018 - Array BioPharma (ARRY) was a big mover last session, as the company saw its shares rise more than 5% on the day amid huge volumes.
Array BioPharma's (ARRY) CEO Ron Squarer on Q3 2018 Results - Earnings Call Transcript https://seekingalpha.com/article/4171824-array-biopharmas-arry-ceo-ron-squarer-q3-2018-results-earnings-call-transcript?source=feed_all_articles May 09, 2018 - Array BioPharma (NASDAQ:ARRY) Q3 2018 Earnings Conference Call May 9, 2018 9:00 AM ET Executives Andrea Flynn - Senior Director, Investor Relations and Corporate Communications Ron Squarer - Chief Exe
Array BioPharma Inc. 2018 Q3 - Results - Earnings Call Slides https://seekingalpha.com/article/4171679-array-biopharma-inc-2018-q3-results-earnings-call-slides?source=feed_all_articles May 09, 2018 - The following slide deck was published by Array BioPharma Inc. in conjunction with their 2018 Q3 earnings call.

Pages: 123456...15

Page 1>
DeepLinks for Array BioPharma
ARRY - Google Finance https://www.google.com/finance?q=ARRY Industry related info and international coverage Summary News
ARRY - Bloomberg http://www.bloomberg.com/research/stocks/snapshot/snapshot.asp?ticker=ARRY Original news and commentary from Bloomberg Charts Financials with pensions Snapshot Earnings Transactions People Options